Total Payments
$9,697
2024 Payments
$1,931
Companies
41
Transactions
200
Medicare Patients
10,119
Medicare Billing
$2.1M
Payment Breakdown by Category
Consulting$5,193 (53.5%)
Food & Beverage$3,577 (36.9%)
Education$927.71 (9.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,193 | 3 | 53.5% |
| Food and Beverage | $3,577 | 179 | 36.9% |
| Education | $927.71 | 18 | 9.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $3,935 | 4 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $1,300 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $629.36 | 36 | $0 (2022) |
| Incyte Corporation | $447.79 | 5 | $0 (2022) |
| Genentech USA, Inc. | $411.79 | 30 | $0 (2024) |
| PFIZER INC. | $304.07 | 16 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $284.47 | 16 | $0 (2024) |
| Merck Sharp & Dohme LLC | $222.80 | 11 | $0 (2024) |
| Foundation Medicine, Inc. | $200.25 | 1 | $0 (2017) |
| EMD Serono, Inc. | $192.44 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,931 | 17 | AstraZeneca Pharmaceuticals LP ($1,593) |
| 2023 | $450.00 | 17 | Janssen Biotech, Inc. ($125.39) |
| 2022 | $415.77 | 18 | Incyte Corporation ($82.95) |
| 2021 | $1,911 | 27 | Karyopharm Therapeutics Inc. ($1,300) |
| 2020 | $2,474 | 8 | AstraZeneca Pharmaceuticals LP ($2,300) |
| 2019 | $700.15 | 30 | Takeda Pharmaceuticals U.S.A., Inc. ($114.63) |
| 2018 | $790.69 | 31 | AbbVie, Inc. ($119.22) |
| 2017 | $1,024 | 52 | Foundation Medicine, Inc. ($200.25) |
All Payment Transactions
200 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: HORMONE THERAPY | ||||||
| 11/11/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: NONE | ||||||
| 09/17/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $15.46 | General |
| Category: Oncology | ||||||
| 09/06/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,592.50 | General |
| 08/29/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $15.34 | General |
| Category: Oncology | ||||||
| 07/15/2024 | GENZYME CORPORATION | CERDELGA (Drug) | Food and Beverage | In-kind items and services | $41.38 | General |
| Category: Genetic Disease | ||||||
| 05/22/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: HEMATOLOGY | ||||||
| 05/07/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: ONCOLOGY | ||||||
| 04/08/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 03/25/2024 | Genentech USA, Inc. | Phesgo (Biological) | Food and Beverage | In-kind items and services | $19.73 | General |
| Category: BioOncology | ||||||
| 03/06/2024 | GENZYME CORPORATION | CEREZYME (Biological), CERDELGA | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: Genetic Disease | ||||||
| 03/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.06 | General |
| Category: ONCOLOGY | ||||||
| 02/05/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: ONCOLOGY | ||||||
| 01/31/2024 | Menarini Silicon Biosystems, Inc. | Cellsearch (Device) | Food and Beverage | Cash or cash equivalent | $16.33 | General |
| Category: Diagnostics | ||||||
| 11/09/2023 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: HORMONE THERAPY | ||||||
| 10/31/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: RESPIRATORY | ||||||
| 09/20/2023 | Genentech USA, Inc. | Phesgo (Biological) | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: BioOncology | ||||||
| 08/31/2023 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $27.39 | General |
| 08/31/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: ONCOLOGY | ||||||
| 07/20/2023 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2023 | EMD Serono, Inc. | TEPMETKO (Drug) | Food and Beverage | Cash or cash equivalent | $19.50 | General |
| Category: Oncology | ||||||
| 06/09/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.36 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 2,421 | 70,086 | $1.6M | $528,985 |
| 2022 | 19 | 2,536 | 78,263 | $1.6M | $558,398 |
| 2021 | 20 | 2,602 | 79,425 | $1.6M | $546,140 |
| 2020 | 20 | 2,560 | 62,346 | $1.4M | $476,453 |
Total Patients
10,119
Total Services
290,120
Medicare Billing
$2.1M
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 2 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 93 | 177 | $48,675 | $11,656 | 23.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 71 | 71 | $31,950 | $10,974 | 34.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 41 | 41 | $29,725 | $7,356 | 24.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 142 | 492 | $24,600 | $6,542 | 26.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 26 | 26 | $14,300 | $5,375 | 37.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 588 | 1,572 | $31,440 | $4,645 | 14.8% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2022 | 19 | 20 | $18,300 | $3,335 | 18.2% |
| 99195 | Drawing of blood for a medical problem | Office | 2022 | 18 | 26 | $9,880 | $2,519 | 25.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 25 | $9,625 | $2,309 | 24.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 14 | $7,000 | $1,788 | 25.5% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 14 | 37 | $4,255 | $1,220 | 28.7% |
| 85610 | Blood test, clotting time | Office | 2022 | 19 | 62 | $930.00 | $258.56 | 27.8% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2022 | 57 | 151 | $604.00 | $197.24 | 32.7% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2021 | 57 | 65,803 | $526,424 | $171,429 | 32.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 41 | 7,740 | $294,120 | $126,870 | 43.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 392 | 898 | $314,300 | $103,178 | 32.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 82 | 233 | $99,025 | $40,528 | 40.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 249 | 362 | $90,500 | $27,901 | 30.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 118 | 214 | $58,850 | $14,549 | 24.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 640 | 1,716 | $42,900 | $13,302 | 31.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 72 | 72 | $32,400 | $10,842 | 33.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 40 | 42 | $30,450 | $8,035 | 26.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 143 | 556 | $27,800 | $7,394 | 26.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 571 | 1,373 | $27,460 | $4,110 | 15.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 20 | 20 | $11,000 | $4,033 | 36.7% |
About Dr. Richard Lee, MD
Dr. Richard Lee, MD is a Hematology & Oncology healthcare provider based in Rockville Centre, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1033118229.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Lee, MD has received a total of $9,697 in payments from pharmaceutical and medical device companies, with $1,931 received in 2024. These payments were reported across 200 transactions from 41 companies. The most common payment nature is "Consulting Fee" ($5,193).
As a Medicare-enrolled provider, Lee has provided services to 10,119 Medicare beneficiaries, totaling 290,120 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Rockville Centre, NY
- Active Since 07/19/2005
- Last Updated 03/09/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1033118229
Products in Payments
- XPOVIO (Drug) $1,300
- OPDIVO (Biological) $210.81
- KEYTRUDA (Biological) $203.14
- FOUNDATIONONE (Device) $200.25
- Imbruvica (Drug) $183.66
- PIQRAY (Drug) $179.22
- IBRANCE (Drug) $165.23
- TECENTRIQ (Biological) $161.62
- ORGOVYX (Drug) $124.24
- Cabometyx (Drug) $120.26
- Venclexta (Drug) $119.22
- Bavencio (Biological) $113.72
- GAZYVA (Biological) $109.75
- KISQALI (Drug) $109.36
- Rubraca (Drug) $99.95
- ERLEADA (Drug) $98.00
- OXBRYTA (Drug) $97.38
- VELCADE (Drug) $95.50
- Phesgo (Biological) $83.25
- LUTATHERA (Drug) $82.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Rockville Centre
Dr. Abdul Mundia, Md, MD
Hematology & Oncology — Payments: $18,207
Hematology & Oncology $18,207
Doron Weiner, Md, MD
Hematology & Oncology — Payments: $7,051
Hematology & Oncology $7,051
Valerie Kremer, M.d, M.D
Hematology & Oncology — Payments: $3,229
Hematology & Oncology $3,229
Dr. Magdy Shaaban, M.d, M.D
Hematology & Oncology — Payments: $3,091
Hematology & Oncology $3,091
Dr. Kenneth Angelino, M.d, M.D
Hematology & Oncology — Payments: $1,529
Hematology & Oncology $1,529
Leonard Kessler, Md, MD
Hematology & Oncology — Payments: $73.56
Hematology & Oncology $73.56